FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385407717> ?p ?o ?g. }

• W4385407717 abstract "Abstract Background Drug resistance limits the treatment effect of cisplatin-based chemotherapy in head and neck squamous cell carcinoma (HNSCC), and the underlying mechanism is not fully understood. The aim of this study was to explore the cause of cisplatin resistance in HNSCC. Methods We performed survival and gene set variation analyses based on HNSCC cohorts and identified the critical role of tumor necrosis factor alpha-induced protein 2 (TNFAIP2) in cisplatin-based chemotherapy resistance. Half-maximal inhibitory concentration (IC50) examination, colony formation assays and flow cytometry assays were conducted to examine the role of TNFAIP2 in vitro, while xenograft models in nude mice and 4-nitroquinoline N-oxide (4NQO)-induced HNSCC models in C57BL/6 mice were adopted to verify the effect of TNFAIP2 in vivo. Gene set enrichment analysis (GSEA) and coimmunoprecipitation coupled with mass spectrometry (Co-IP/MS) were performed to determine the mechanism by which TNFAIP2 promotes cisplatin resistance. Results High expression of TNFAIP2 is associated with a poor prognosis, cisplatin resistance, and low reactive oxygen species (ROS) levels in HNSCC. Specifically, it protects cancer cells from cisplatin-induced apoptosis by inhibiting ROS-mediated c-JUN N-terminal kinase (JNK) phosphorylation. Mechanistically, the DLG motif contained in TNFAIP2 competes with nuclear factor-erythroid 2-related factor 2 (NRF2) by directly binding to the Kelch domain of Kelch-like ECH-associated protein 1 (KEAP1), which prevents NRF2 from undergoing ubiquitin proteasome-mediated degradation. This results in the accumulation of NRF2 and confers cisplatin resistance. Positive correlations between TNFAIP2 protein levels and NRF2 as well as its downstream target genes were validated in HNSCC specimens. Moreover, the small interfering RNA (siRNA) targeting TNFAIP2 significantly enhanced the cisplatin treatment effect in a 4NQO-induced HNSCC mouse model. Conclusions Our results reveal the antioxidant and cisplatin resistance-regulating roles of the TNFAIP2/KEAP1/NRF2/JNK axis in HNSCC, suggesting that TNFAIP2 might be a potential target in improving the cisplatin treatment effect, particularly for patients with cisplatin resistance." @default.
• W4385407717 created "2023-08-01" @default.
• W4385407717 creator A5011903670 @default.
• W4385407717 creator A5017133568 @default.
• W4385407717 creator A5029551575 @default.
• W4385407717 creator A5031044167 @default.
• W4385407717 creator A5039989945 @default.
• W4385407717 creator A5043713872 @default.
• W4385407717 creator A5043834938 @default.
• W4385407717 creator A5045696992 @default.
• W4385407717 creator A5046592419 @default.
• W4385407717 creator A5055838753 @default.
• W4385407717 creator A5059039253 @default.
• W4385407717 creator A5066505627 @default.
• W4385407717 creator A5069813415 @default.
• W4385407717 creator A5074942308 @default.
• W4385407717 creator A5084409831 @default.
• W4385407717 creator A5084768375 @default.
• W4385407717 date "2023-08-01" @default.
• W4385407717 modified "2023-10-16" @default.
• W4385407717 title "TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling" @default.
• W4385407717 cites W1674293076 @default.
• W4385407717 cites W2002015567 @default.
• W4385407717 cites W2023598683 @default.
• W4385407717 cites W2023964913 @default.
• W4385407717 cites W2075562229 @default.
• W4385407717 cites W2096332232 @default.
• W4385407717 cites W2098075173 @default.
• W4385407717 cites W2112845420 @default.
• W4385407717 cites W2118422955 @default.
• W4385407717 cites W2122052370 @default.
• W4385407717 cites W2128490578 @default.
• W4385407717 cites W2135594199 @default.
• W4385407717 cites W2140955917 @default.
• W4385407717 cites W2145487126 @default.
• W4385407717 cites W2168152640 @default.
• W4385407717 cites W2491518216 @default.
• W4385407717 cites W2561420332 @default.
• W4385407717 cites W2763201457 @default.
• W4385407717 cites W2801896245 @default.
• W4385407717 cites W2897079052 @default.
• W4385407717 cites W2922415295 @default.
• W4385407717 cites W2956019456 @default.
• W4385407717 cites W2968430536 @default.
• W4385407717 cites W2974996663 @default.
• W4385407717 cites W2982979216 @default.
• W4385407717 cites W2988154783 @default.
• W4385407717 cites W3031111846 @default.
• W4385407717 cites W3045369651 @default.
• W4385407717 cites W3096681080 @default.
• W4385407717 cites W3097529117 @default.
• W4385407717 cites W3105903630 @default.
• W4385407717 cites W3128646645 @default.
• W4385407717 cites W3153729378 @default.
• W4385407717 cites W3156283008 @default.
• W4385407717 cites W3195081883 @default.
• W4385407717 cites W4205537283 @default.
• W4385407717 cites W4280614756 @default.
• W4385407717 cites W4296629504 @default.
• W4385407717 cites W952491933 @default.
• W4385407717 doi "https://doi.org/10.1186/s13046-023-02775-1" @default.
• W4385407717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37525222" @default.
• W4385407717 hasPublicationYear "2023" @default.
• W4385407717 type Work @default.
• W4385407717 citedByCount "1" @default.
• W4385407717 crossrefType "journal-article" @default.
• W4385407717 hasAuthorship W4385407717A5011903670 @default.
• W4385407717 hasAuthorship W4385407717A5017133568 @default.
• W4385407717 hasAuthorship W4385407717A5029551575 @default.
• W4385407717 hasAuthorship W4385407717A5031044167 @default.
• W4385407717 hasAuthorship W4385407717A5039989945 @default.
• W4385407717 hasAuthorship W4385407717A5043713872 @default.
• W4385407717 hasAuthorship W4385407717A5043834938 @default.
• W4385407717 hasAuthorship W4385407717A5045696992 @default.
• W4385407717 hasAuthorship W4385407717A5046592419 @default.
• W4385407717 hasAuthorship W4385407717A5055838753 @default.
• W4385407717 hasAuthorship W4385407717A5059039253 @default.
• W4385407717 hasAuthorship W4385407717A5066505627 @default.
• W4385407717 hasAuthorship W4385407717A5069813415 @default.
• W4385407717 hasAuthorship W4385407717A5074942308 @default.
• W4385407717 hasAuthorship W4385407717A5084409831 @default.
• W4385407717 hasAuthorship W4385407717A5084768375 @default.
• W4385407717 hasBestOaLocation W43854077171 @default.
• W4385407717 hasConcept C121608353 @default.
• W4385407717 hasConcept C126322002 @default.
• W4385407717 hasConcept C153911025 @default.
• W4385407717 hasConcept C185592680 @default.
• W4385407717 hasConcept C190283241 @default.
• W4385407717 hasConcept C2776530083 @default.
• W4385407717 hasConcept C2776694085 @default.
• W4385407717 hasConcept C2776833033 @default.
• W4385407717 hasConcept C2778239845 @default.
• W4385407717 hasConcept C502942594 @default.
• W4385407717 hasConcept C553184892 @default.
• W4385407717 hasConcept C55493867 @default.
• W4385407717 hasConcept C71924100 @default.
• W4385407717 hasConcept C86803240 @default.
• W4385407717 hasConceptScore W4385407717C121608353 @default.
• W4385407717 hasConceptScore W4385407717C126322002 @default.
• W4385407717 hasConceptScore W4385407717C153911025 @default.

• next